Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19000200 | KRAS G12D MODULATING COMPOUNDS | December 2024 | May 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18986415 | Method of treating post-traumatic stress disorder with carpipramine | December 2024 | March 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 18941779 | USES OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCIN | November 2024 | March 2025 | Allow | 4 | 0 | 1 | Yes | No |
| 18885140 | FATTY ACID COMPOSITIONS | September 2024 | April 2025 | Allow | 7 | 2 | 2 | Yes | No |
| 18743944 | Use of Deuterated Empathogens as Therapeutic Agents | June 2024 | September 2024 | Allow | 3 | 0 | 1 | Yes | No |
| 18718086 | USE OF FLIBANSERIN IN PREPARATION OF DRUG FOR TREATING ANDROGENIC ALOPECIA | June 2024 | November 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18631828 | CONTROLLED RELEASE STERILE INJECTABLE ARIPIPRAZOLE FORMULATION AND METHOD | April 2024 | June 2025 | Abandon | 14 | 0 | 1 | No | No |
| 18522440 | METHOD FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | November 2023 | June 2025 | Allow | 19 | 0 | 1 | No | No |
| 18494382 | C1-SUBSTITUTED ISOPROPYLAMINE FUSED HETEROCYCLIC MESCALINE DERIVATIVES | October 2023 | September 2024 | Allow | 11 | 2 | 1 | Yes | No |
| 18225992 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | July 2023 | April 2025 | Allow | 20 | 0 | 1 | Yes | No |
| 18222720 | EXTRACTION OF ABSCISIC ACID FROM STRAWBERRIES | July 2023 | November 2024 | Abandon | 16 | 3 | 0 | No | No |
| 18341626 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | June 2023 | May 2025 | Allow | 22 | 0 | 1 | Yes | No |
| 18302997 | USE OF (S)-3-AMINO-4-(DIFLUOROMETHYLENYL) CYCLOPENT-1-ENE-1-CARBOXYLIC ACID AND RELATED COMPOUNDS, (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND VIGABATRIN IN THE TREATMENT OF DEVELOPMENTAL DISORDERS | April 2023 | December 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 18178429 | Methods for Treating Systemic Lupus Erythematosus | March 2023 | May 2025 | Abandon | 27 | 0 | 1 | No | No |
| 17991154 | COMPOSITIONS AND METHODS FOR IMMUNE-MEDIATED CANCER THERAPY | November 2022 | March 2025 | Allow | 27 | 0 | 1 | Yes | No |
| 17988916 | DIROFILARIA VOLATILE ORGANIC COMPOUND SIGNATURES AND USES THEREOF | November 2022 | April 2025 | Abandon | 29 | 0 | 1 | No | No |
| 18052814 | SELENOGALACTOSIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES ASSOCIATED WITH GALECTIN AND THE USE THEREOF | November 2022 | March 2025 | Abandon | 28 | 0 | 1 | No | No |
| 17997438 | PURINE DERIVATIVES AS SIK-3 INHIBITORS | October 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 18046064 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | October 2022 | September 2024 | Allow | 23 | 0 | 1 | Yes | No |
| 17934107 | SYK KINASE INHIBITORS AS TREATMENT FOR MALARIA | September 2022 | May 2025 | Abandon | 32 | 2 | 1 | Yes | No |
| 17945427 | TOPICAL MINOCYCLINE OINTMENT FOR SUPPRESSION OF ALLERGIC SKIN RESPONSES | September 2022 | October 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17822934 | PRECURSOR COMPOUNDS FOR MOLECULAR COATINGS | August 2022 | September 2024 | Allow | 25 | 0 | 0 | Yes | No |
| 17817753 | USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | August 2022 | October 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17877163 | PYRIMIDINE COMPOUNDS AND USE THEREOF | July 2022 | November 2023 | Allow | 15 | 1 | 0 | Yes | No |
| 17871584 | METHODS OF STRATIFYING PATIENTS FOR TREATMENT WITH RETINOIC ACID RECEPTOR-ALPHA AGONISTS | July 2022 | May 2025 | Abandon | 34 | 1 | 0 | No | No |
| 17869993 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | July 2022 | October 2024 | Abandon | 27 | 0 | 1 | No | No |
| 17838308 | USE OF ANAMORELIN TO TREAT CANCER-RELATED FATIGUE | June 2022 | February 2025 | Abandon | 33 | 0 | 1 | No | No |
| 17746250 | NUTRITIONAL PRODUCT | May 2022 | December 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17730470 | USE OF A DPP-4 INHIBITOR IN SIRS AND/OR SEPSIS | April 2022 | January 2025 | Allow | 33 | 2 | 1 | Yes | No |
| 17700317 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | March 2022 | February 2025 | Allow | 35 | 3 | 0 | Yes | No |
| 17634729 | Methods of Treating Psychological and Brain Disorders | February 2022 | November 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17586206 | METHODS FOR TREATING CORONAVIRUS INFECTION | January 2022 | May 2025 | Abandon | 39 | 3 | 0 | Yes | No |
| 17585415 | USE OF THE PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH A STANDARD ANTI-EPILEPTIC DRUG (SAED) IN THE TREATMENT OF EPILEPSY | January 2022 | March 2025 | Allow | 38 | 2 | 1 | No | No |
| 17625604 | METHODS AND COMPOSITIONS FOR UNSILENCING IMPRINTED GENES | January 2022 | March 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17569887 | ORALLY INHALED AND NASAL BENZODIAZEPINES | January 2022 | May 2025 | Abandon | 40 | 4 | 0 | No | No |
| 17546843 | INHIBITORS OF EZH2 AND METHODS OF USE THEREOF | December 2021 | April 2025 | Abandon | 40 | 3 | 0 | Yes | No |
| 17534795 | ANTI-VIRAL ACTIVITY OF VPS34 INHIBITORS | November 2021 | May 2025 | Allow | 41 | 4 | 0 | No | No |
| 17528444 | Antimicrobial Composition | November 2021 | February 2025 | Abandon | 39 | 3 | 0 | Yes | No |
| 17604619 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | October 2021 | September 2024 | Allow | 35 | 0 | 1 | Yes | No |
| 17445463 | TREATMENT OF MIGRAINE | August 2021 | February 2025 | Abandon | 42 | 2 | 1 | Yes | Yes |
| 17330122 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING A CYTOCHROME P450 PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | May 2021 | May 2025 | Abandon | 48 | 6 | 2 | Yes | No |
| 17295351 | INHIBITORS OF GLI1 AS THERAPEUTIC AGENTS | May 2021 | September 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17293124 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | May 2021 | October 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17238909 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION | April 2021 | February 2025 | Abandon | 46 | 2 | 1 | Yes | No |
| 17131911 | INHIBITORS OF SHORT-CHAIN DEHYDROGENASE ACTIVITY FOR TREATING FIBROSIS | December 2020 | March 2024 | Allow | 39 | 3 | 0 | No | No |
| 17075167 | COMPOSITIONS COMPRISING MACROCYCLE DERIVATIVES INCORPORATING BRIDGED MACROCYCLES AND METHODS OF PRODUCING AND USING SAME | October 2020 | August 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 16970384 | CANCER TREATMENT USING COMBINATION OF NEUTROPHIL MODULATOR WITH MODULATOR OF IMMUNE CHECKPOINT | August 2020 | December 2024 | Abandon | 52 | 2 | 1 | No | No |
| 16715976 | METHOD OF USE OF NOVEL NAPROXEN DERIVATIVES | December 2019 | February 2020 | Allow | 2 | 0 | 0 | Yes | No |
| 16428056 | Dosing Regimen for the Treatment of PI3K Related Disorders | May 2019 | July 2023 | Allow | 50 | 4 | 1 | No | Yes |
| 16399590 | Naproxen-Based Non-Steroidal Anti-Inflammatory Drug with Low Gastric Toxicity | April 2019 | September 2019 | Allow | 5 | 0 | 0 | Yes | No |
| 16396083 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA-CD47 INTERACTION | April 2019 | April 2025 | Abandon | 60 | 7 | 1 | Yes | Yes |
| 16298824 | Melatonin for Preventing and Treating Radiation Cystitis | March 2019 | June 2025 | Allow | 60 | 7 | 1 | Yes | Yes |
| 16199875 | MACROCYCLIC COMPOUNDS AS ROS1 KINASE INHIBITORS | November 2018 | January 2020 | Allow | 14 | 2 | 1 | Yes | No |
| 16027988 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | July 2018 | August 2019 | Allow | 13 | 1 | 1 | Yes | No |
| 15765960 | COMPOUNDS AND COMPOSITIONS HAVING KNOCK-DOWN OR BLOOD FEED INHIBITION ACTIVITY AGAINST INSECT PESTS | April 2018 | December 2024 | Allow | 60 | 3 | 1 | Yes | Yes |
| 15921138 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | March 2018 | August 2019 | Allow | 17 | 1 | 1 | Yes | No |
| 15897889 | COMPOSITIONS CONTAINING AROMATIC ALDEHYDES AND THEIR USE IN TREATMENTS | February 2018 | February 2020 | Allow | 24 | 1 | 1 | No | No |
| 15882548 | COMPOUND USEFUL FOR THE TREATMENT OF NONSENSE-MUTATION-MEDIATED DISEASES AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUND | January 2018 | December 2018 | Allow | 10 | 0 | 0 | No | No |
| 15477160 | CREATINE ESTER PRONUTRIENT COMPOUNDS AND FORMULATIONS | April 2017 | August 2019 | Allow | 29 | 4 | 1 | Yes | No |
| 15452376 | CHLOROPHYLL C CONTAINING DEGRANULATION SUPPRESSOR | March 2017 | April 2017 | Allow | 1 | 0 | 0 | Yes | No |
| 15504514 | ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND | February 2017 | April 2019 | Allow | 26 | 3 | 1 | Yes | No |
| 15423485 | METHODS AND COMPOSITIONS FOR TREATING HEARING DISORDERS | February 2017 | May 2019 | Allow | 28 | 0 | 1 | Yes | No |
| 15350427 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | November 2016 | February 2018 | Allow | 15 | 1 | 1 | Yes | No |
| 15301523 | METHOD FOR USE OF HOMOPIPERAZINIUM COMPOUNDS IN THE TREATMENT OF CANCER | October 2016 | November 2017 | Allow | 14 | 0 | 1 | Yes | No |
| 15273404 | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISEASE | September 2016 | July 2018 | Allow | 21 | 1 | 1 | Yes | No |
| 15120002 | SUBSTITUTED CYCLOPENTANES, TETRAHYDROFURANES AND PYRROLIDINES AS OREXIN RECEPTOR ANTAGONISTS | August 2016 | June 2017 | Allow | 10 | 0 | 1 | Yes | No |
| 15219518 | Phosphodiesesterase 4 Inhibitors for the Treatment of a Cognitive Deficit | July 2016 | September 2018 | Allow | 26 | 1 | 1 | Yes | No |
| 14897590 | 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF | December 2015 | January 2017 | Allow | 14 | 0 | 1 | Yes | No |
| 14597453 | METHOD FOR THE TREATMENT OR PREVENTION OF LOWER URINARY TRACT SYMPTOMS | January 2015 | April 2015 | Allow | 3 | 0 | 0 | Yes | No |
| 14571511 | USE OF EDELFOSINE AND OTHER SYNTHETIC ETHER ALKYL-LYSOPHOSPHOLIPIDS (APLs) FOR SEIZURES AND RELATED DISEASES | December 2014 | July 2016 | Allow | 19 | 0 | 1 | Yes | No |
| 14566465 | Pharmaceutical Composition, Substrate Comprising A Pharmaceutical Composition, And Use Of A Pharmaceutical Composition | December 2014 | January 2018 | Allow | 37 | 2 | 1 | Yes | No |
| 14548524 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | November 2014 | February 2017 | Allow | 27 | 0 | 1 | Yes | No |
| 14524721 | Lipid-Lowering Antidiabetic Agent | October 2014 | August 2015 | Allow | 10 | 0 | 1 | Yes | No |
| 14462207 | COMPOSITION AND METHOD FOR AFFECTING OBESITY AND RELATED CONDITIONS | August 2014 | November 2014 | Allow | 3 | 0 | 0 | Yes | No |
| 14374573 | METHODS FOR TREATING ALZHEIMER'S DISEASE BY ADMINISTERING CERTAIN SYNTHETIC COMPOUNDS | July 2014 | March 2015 | Allow | 7 | 0 | 1 | Yes | No |
| 14336911 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | July 2014 | October 2015 | Allow | 15 | 1 | 1 | No | No |
| 14336341 | COMPOSITION FOR TREATING INFLUENZA A (H1N1) VIRUS AND A PREPARATION METHOD THEREFOR | July 2014 | December 2014 | Allow | 5 | 0 | 0 | Yes | No |
| 14367638 | CHLOROPHYLL c CONTAINING DEGRANULATION SUPPRESSOR | June 2014 | February 2017 | Allow | 32 | 2 | 1 | Yes | No |
| 14249914 | USE AND APPLICATION OF A PHARMACEUTICAL COMPOSITION CONTAINING A MIXTURE OF NATURAL-ORIGIN HETEROCYCLICAL GUANIDINE, FOR COSMETOLOGY, WOUND HEALING, FOCAL DYSTONIA AND MUSCULAR SPASM- RELATED CLINICAL PATHOLOGIES | April 2014 | June 2014 | Allow | 2 | 0 | 1 | Yes | No |
| 14244278 | METHODS OF TREATING AGE RELATED DISORDERS | April 2014 | May 2016 | Allow | 26 | 0 | 1 | Yes | No |
| 14215889 | METHOD FOR TREATING NEURODEGENERATION USING A p38MAPK INHIBITOR | March 2014 | March 2015 | Allow | 12 | 0 | 1 | Yes | No |
| 14178425 | METHODS FOR TREATING DEPRESSION, NEURODEGENERATION, INHIBITING AMYLOID BETA DEPOSITION, DELAYING SENESCENCE, AND EXTENDING LIFE SPANS WITH HETEROCYCLIC COMPOUNDS | February 2014 | March 2015 | Allow | 13 | 2 | 1 | Yes | No |
| 14136843 | LIPID-LOWERING ANTIDIABETIC AGENT | December 2013 | February 2015 | Allow | 14 | 1 | 1 | Yes | No |
| 14006170 | PYRAZOLE COMPOUNDS AS CRTH2 ANTAGONISTS | December 2013 | October 2015 | Allow | 25 | 0 | 1 | Yes | No |
| 14091218 | COMPOSITION AND METHOD FOR AFFECTING OBESITY AND RELATED CONDITIONS | November 2013 | April 2014 | Allow | 4 | 0 | 0 | Yes | No |
| 14042891 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMERS DISEASE, TYPE 2 DIABETES, AND PARKINSONS DIS39S | October 2013 | July 2014 | Allow | 9 | 2 | 1 | Yes | No |
| 14043634 | USE AND APPLICATION OF A PHARMACEUTICAL COMPOSITION CONTAINING A MIXTURE OF NATURAL-ORIGIN HETEROCYCLICAL GUANIDINE, FOR COSMETOLOGY, WOUND HEALING, FOCAL DYSTONIA AND MUSCULAR SPASM- RELATED CLINICAL PATHOLOGIES | October 2013 | June 2014 | Allow | 9 | 0 | 1 | Yes | No |
| 14028960 | METHOD FOR IMPROVING TETRACYCLINE-RESISTANCE OF ACINETOBACTER BAUMANNII | September 2013 | May 2014 | Allow | 8 | 1 | 1 | No | No |
| 13970026 | METHOD FOR THE TREATMENT OR PREVENTION OF LOWER URINARY TRACT SYMPTOMS | August 2013 | October 2014 | Allow | 14 | 2 | 0 | Yes | No |
| 13942158 | TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF | July 2013 | May 2015 | Allow | 22 | 0 | 1 | Yes | No |
| 13925271 | TREATMENT OR PREVENTION OF HYPOTENSION AND SHOCK | June 2013 | March 2015 | Allow | 21 | 1 | 1 | Yes | No |
| 13923829 | LIPID-LOWERING ANTIDIABETIC AGENT | June 2013 | September 2014 | Allow | 14 | 4 | 0 | Yes | No |
| 13915833 | Combination Medicaments for Treating Bacterial Infections | June 2013 | April 2014 | Allow | 10 | 0 | 1 | Yes | No |
| 13992795 | NEW TRIAZOLE COMPOUNDS AS POTENTIAL ANTI-INFLAMMATORY AGENTS | June 2013 | May 2014 | Allow | 11 | 2 | 1 | Yes | No |
| 13897524 | NOVEL ROCK INHIBITORS | May 2013 | June 2014 | Allow | 13 | 0 | 1 | Yes | No |
| 13885500 | Benzofuran Compounds For The Treatment Of Hepatitis C Virus Infections | May 2013 | September 2014 | Allow | 16 | 1 | 1 | Yes | No |
| 13884741 | LACTAM DERIVATIVES USEFUL AS OREXIN RECEPTOR ANTAGONISTS | May 2013 | August 2015 | Allow | 28 | 0 | 1 | Yes | No |
| 13887762 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES SUCH AS ALZHEIMER'S DISEASE, TYPE 2 DIABETES, AND PARKINSON'S DISEASE | May 2013 | February 2015 | Allow | 21 | 1 | 1 | Yes | No |
| 13836816 | Benzimidazole-imidazole derivatives | March 2013 | April 2016 | Allow | 37 | 4 | 1 | Yes | No |
| 13822149 | USE OF DERIVATIVES OF PENTAPHYRINE AS ANTIMICROBIAL AND DISINFECTANT AGENTS | March 2013 | September 2014 | Allow | 18 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHONG, YONG SOO.
With a 64.3% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 42.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner CHONG, YONG SOO works in Art Unit 1623 and has examined 182 patent applications in our dataset. With an allowance rate of 87.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 35 months.
Examiner CHONG, YONG SOO's allowance rate of 87.9% places them in the 64% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by CHONG, YONG SOO receive 1.96 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by CHONG, YONG SOO is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +32.2% benefit to allowance rate for applications examined by CHONG, YONG SOO. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.1% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 49.3% of cases where such amendments are filed. This entry rate is in the 69% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 111.1% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 78% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 70.8% of appeals filed. This is in the 53% percentile among all examiners. Of these withdrawals, 52.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 37.5% are granted (fully or in part). This grant rate is in the 34% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 6.0% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.2% of allowed cases (in the 59% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.